Oncobiotek Formulations Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.82 M
- Revenue Growth 60.63%
- Profit Growth -50.72%
- Ebitda 48.95%
- Net Worth 12.85%
- Total Assets 46.02%
About Oncobiotek Formulations
Oncobiotek Formulations Private Limited (OFPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 June 2018 (Six years and eight months 1 days old ). Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹8.82 M.
Haresh Khetwani and Rajesh Sharma serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24290GJ2018PTC102902
-
Company No.
102902
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
18 Jun 2018
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Oncobiotek Formulations?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Sharma
|
Director | 18-Jun-2018 | Current |
|
Haresh Khetwani
|
Director | 18-Jun-2018 | Current |
Financial Performance of Oncobiotek Formulations.
Oncobiotek Formulations Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 60.63% increase. The company also saw a substantial fall in profitability, with a 50.72% decrease in profit. The company's net worth Soared by an impressive increase of 12.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oncobiotek Formulations?
In 2023, Oncobiotek Formulations had a public holding of 80.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Oncobiotek Drugs Private LimitedHaresh Khetwani and Rajesh Sharma are mutual person
Charges (Loans)
₹8.82 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.88 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Oct 2021 | Others | ₹8.82 M | Open |
How Many Employees Work at Oncobiotek Formulations?
Oncobiotek Formulations has a workforce of 52 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oncobiotek Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oncobiotek Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.